GLP-1 Family advanced
GLP-1/GIP/Glucagon Triple Agonists
Triple incretin receptor agonists simultaneously activating GLP-1, GIP, and glucagon receptors for maximal metabolic benefit.
By Encyclopeptide Editorial | 1 min read
GLP-1 GIP glucagon triple-agonist obesity
Overview
Triple agonists represent the cutting edge of incretin-based therapy, simultaneously activating GLP-1, GIP, and glucagon receptors.
Clinical Candidates
Retatrutide (Eli Lilly)
- Mechanism: GLP-1/GIP/glucagon triple agonist
- Phase 3: TRIUMPH program
- Phase 2 results: Up to 24.2% weight loss at 48 weeks
Pemvidutide (Altimmune)
- Mechanism: GLP-1/glucagon dual agonist (glucagon bias)
- Phase 2: Up to 15.6% weight loss at 48 weeks
Chemical Identity
| Property | Value |
|---|---|
| Name | GLP-1/GIP/Glucagon Triple Agonists |
| Category | GLP-1 Family |
References
- Encyclopeptide Database. “GLP-1/GIP/Glucagon Triple Agonists” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about GLP-1/GIP/Glucagon Triple Agonists with interactive quizzes on Wikipept.
Take a Quiz on Wikipept